Document is current
Any future updates will be listed below
-
Authors
Ávila-Nieto, Carlos
Vergara-Alert, Júlia
Amengual-Rigo, Pep
Ainsua-Enrich, Erola
Brustolin, Marco https://orcid.org/0000-0002-3594-4488
Rodríguez de la Concepción, María Luisa
Pedreño-Lopez, Núria https://orcid.org/0000-0001-6927-2301
Rodon, Jordi https://orcid.org/0000-0002-1032-9091
Urrea, Victor https://orcid.org/0000-0002-2577-856X
Pradenas, Edwards https://orcid.org/0000-0001-5162-8920
Marfil, Silvia
Ballana, Ester
Riveira-Muñoz, Eva
Pérez, Mònica
Roca, Núria
Tarrés-Freixas, Ferran
Cantero, Guillermo
Pons-Grífols, Anna https://orcid.org/0000-0002-8402-3941
Rovirosa, Carla
Aguilar-Gurrieri, Carmen https://orcid.org/0000-0002-5701-7650
Ortiz, Raquel
Barajas, Ana
Trinité, Benjamin https://orcid.org/0000-0003-3809-042X
Lepore, Rosalba
Muñoz-Basagoiti, Jordana https://orcid.org/0000-0002-0384-5928
Perez-Zsolt, Daniel https://orcid.org/0000-0003-4192-7622
Izquierdo-Useros, Nuria https://orcid.org/0000-0002-1039-1821
Valencia, Alfonso https://orcid.org/0000-0002-8937-6789
Blanco, Julià https://orcid.org/0000-0002-2225-0217
Guallar, Victor https://orcid.org/0000-0002-4580-1114
Clotet, Bonaventura https://orcid.org/0000-0003-3232-4598
Segalés, Joaquim https://orcid.org/0000-0002-1539-7261
Carrillo, Jorge https://orcid.org/0000-0003-0221-5948
-
Funding
Funding for this research was provided by:
Generalitat de Catalunya (SLD0015, 2020 FI_B_0742, 2020FI_B2_00138, 2022 FI_B_00698, SLD0016, 2021SGR00452)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI18/01332, PI17/01518)
Grifols Pharmaceutical support the present study Yomecorono was a crowdfunding project.
Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (PID2020-117145RB-I00)
Grifols Pharmaceutical support the present study Yomecorono, BonePreu/Esclat, and Correos were crowdfunding projects.
- License Information
-
More Information
Article History
Received: 21 April 2023
Accepted: 27 February 2024
First Online: 21 March 2024
Competing interests
: The present work counted on funding from Grifols pharmaceutical. However, Grifols had no role in study design, data analysis, decision to publish or manuscript preparation. P.A.R. is currently employed by Sanofi, which has no association with any content related to this work. The authors declare no other competing interests. Unrelated to the submitted work, J.B. and J.C. are founders and shareholders of AlbaJuna Therapeutics, S.L. B.C. is founder and shareholder of AlbaJuna Therapeutics, S.L. and AELIX Therapeutics, S.L, and V.G. is founder and shareholder of Nostrum Biodiscovery. Unrelated to the submitted work, N.I.-U. is supported by institutional funding from Pharma Mar, HIPRA, Amassence, and Palobiofarma.
